FILING ANALYSIS · MONDAY, NOVEMBER 16
ENANTA PHARMACEUTICALS INC ENTA — 8-K: Results of Operations and Financial Condition
neutral
Enanta Pharmaceuticals reported fiscal Q4 and year-end results with total revenue of $12.9 million and $63.0 million, respectively, and a cash runway expected to fund operations into fiscal 2029, but the decrease in revenue due to a decline in AbbVie's sales of MAVYRET/MAVIRET may impact investor sentiment
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →